<a href="https://laohu8.com/S/AEMD">Aethlon Medical Inc</a>. Announces $4.5 Million Public Offering of Common Stock and Warrants
Aethlon Medical Inc., a company specializing in medical therapeutics for cancer and infectious diseases, has announced the pricing of a public offering valued at approximately $4.5 million. The offering includes 5,000,000 shares of common stock, or prefunded warrants in lieu thereof, and warrants to purchase an additional 5,000,000 shares of common stock. Each share or prefunded warrant, along with the accompanying warrant, is priced at $0.90. The warrants are exercisable immediately and will expire five years from the date of issuance. The company plans to utilize the proceeds for general corporate purposes, including clinical trials, research and development, capital expenditures, and working capital. Maxim Group LLC is serving as the exclusive placement agent for this transaction.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-25-006788), on September 09, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.